RADIOTHERAPY AND IMMMUN RESPONCE IS THE RADIOTHERAPY VACCINE? GOOD NEWS?

Öz

SUMMARY/ABSTRACT: Radiotherapy (RT) activates immun responce. Because of this we must discuss the question of “is the radiotherapy vaccine”. If RT increases the immun responce we must learn some more about the RT effects on the cells, cell surface antigene, immun checkpoints and their inhibition (ICI; CTLA4, PD1, PDL1 inhibition). In this review it will be discussed the role of the radiotherapy and biologic effects of the radiotherapy to activate the immun responce, radiotherapy dose, radiotherapy timing and the side effects of immun checkpoints inhibitors.

RADYOTERAPİ VE İMMUN YANIT RADYOTERAPİ AŞIMIDIR? İYİ HABER?

Öz

ÖZET: Radyoterapi (RT) immün yanıtı aktive etmektedir. Bundan dolayı “radyoterapi aşımıdır” sorusunu tartışmak gerekmektedir. RT, immün yanıtı artırıyorsa, hücrelerdeki RT etkileri, hücre yüzeyi antijeni, immün kontrol noktaları ve bunların inhibisyonu hakkında daha fazla bilgi edinmeliyiz (ICI; CTLA4, PD1, PDL1 inhibisyonu). Bu derlemede, radyoterapinin ve biyolojik etkilerinin immun cevabı aktive etmede ki rolü, radyoterapi dozu, radyoterapi zamanlaması ve immun kontrol noktaları baskılayıcılarının yan etkileri tartışılacaktır.

Anahtar Kelimeler

• Radyoterapi,immun yanıt,immun kontrol noktaları

Kaynakça

1. 1. E. M. Akinoglu, K. Ozbilgin, P. Kilicaslan Sonmez, M. M. Ozkut, M. Giersig, S. Inan, E. Gumustepe, C. Kurtman, Biocompatibility of vertically aligned multi-walled carbon nanotube scaffolds for human breast cancer cell line MDA-MB-231. Progress in Biomaterials. 2017; 6: 189-96.2. Purdy JA, Current ICRU definitions of volumes: limitations and future directions. Semin Radiat Oncol. 2004;14: 27-40.3. Pajonk F, Vlashi E, WH, Radiation Resistance of Cancer Stem Cells: The 4 R’s of Radiobiology Revisited Stem Cells. 2010; 28: 639-48.4. Redelman-Sidi G, Glickman MS, Bochner BH, The mechanism of action of BCG therapy for bladder cancer - a current perspective. Nature Reviews Urology. 2014; 11, 153-62.5. Rodríguez PC, Rodríguez G, González G, Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev. 2010; 12: 17-23.6. Saavedra D, Crombet T, CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. Front Immunol. 2017; 8: 1-7 7. Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol. 2018;15: 477-94. 8. Esposito A, Criscitiello C, Curigliano G. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. Curr Opin Oncol. 2015; 27: 445-51.9. Manda K, Glasow A, Paape D, Hildebrandt G, Effects of ionizing radiation on the immune system with special emphasis on the interaction of dendritic and T cells. Front Oncol. 2012; 2: 1-9.10. Demaria S, Golden EB, Formenti SC. Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol. 2015;1:1325-32.11. Demaria S, Coleman CN, Formenti SC. Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer. 2016; 2: 286-94.12. Shi X, Shiao SL. The role of macrophage phenotype in regulating the response to radiation therapy. Transl Res. 2018; 191: 64-80. 13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74.14. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014; 5:403-16.15. Kaur P, Asea A, Radiation-induced effects and the immune system in cancer. Front Oncol. 2012; 2: 1-10.16. Hu ZI, McArthur HL, Ho AY, The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer? Curr Breast Cancer Rep. 2017; 9: 45-51.17. Jatoi I, Benson JR, Kunkler I, Hypothesis: can the abscopal effect explain the impact of adjuvant radiotherapy on breast cancer mortality? NPJ Breast Cancer. 2018; 4: 1-8.18. Zhang X, Niedermann G, Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response. IJ Rad Oncol Biol Phys. 2018; 101: 63-73.19. Formenti SC, Demaria S, Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift. J Natl Cancer Inst. 2013; 105: 256-65.20. Garon EB, Rizvi NA, Hui R, et al, for the KEYNOTE-001 Investigators. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. N Engl J Med. 2015; 372:2018-28.21. Antonia SJ, Villegas A, Daniel D, et al, for the PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377: 1919-29.
2. 22. Winer A, Bodor JN, Borghaei H, Identifying and managing the adverse effects of immune checkpoint blockadeJ Thorac Dis. 2018; 10 (Suppl 3): 480-9.23. Kähler KC, Hassel JC, Heinzerling L, et al for the “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO). Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges. 2016; 14: 662-81.
3. 24. Wang Y, Deng W, Li N, et al, Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Front Pharmacol. 2018; 9: 1-11.
4. 25. Ebner DK, Tinganelli W, Helm A, et al, The Immunoregulatory Potential of Particle Radiation in Cancer Therapy. Front Immunol. 2017; 8: 1-8.